Abstract
Background
Preoperative carcinoembryonic antigen (CEA) has been reported as a prognostic factor in patients with colorectal liver metastasis (CRLM) after hepatectomy. However, the impact of a preoperative “CEA uptrend” on prognosis after hepatectomy in these patients remains unknown. This study assessed the impact of CEA uptrend on prognosis in patients undergoing hepatectomy for CRLM.
Methods
Consecutive patients with CRLM who underwent hepatectomy between 2009 and 2018 were retrospectively analyzed. Patients with CRLM for whom CEA was measured both around 1 month before (CEA-1m) and within 3 days (CEA-3d) before hepatectomy were enrolled. A CEA-3d higher than both the upper limit of normal (5 ng/ml) and CEA-1m was defined as a CEA uptrend.
Results
Study participants comprised 212 patients with CRLM. Of these, 88 patients (41.5%) showed a CEA uptrend. CEA uptrend indicated better discriminatory ability (corrected Akaike information criteria, 733.72) and homogeneity (likelihood ratio chi-square value, 18.80) than CEA-3d or CEA-1m. Patients with CEA uptrend showed poorer overall survival than those without CEA uptrend (p < 0.001). After adjusting for known prognostic factors, the prognostic significance of CEA uptrend retained (hazard ratio 2.63, 95% confidence interval 1.63–4.26, p < 0.001). In subgroup analyses, the prognostic significance of CEA uptrend was retained irrespective of the status of RAS mutation or response to preoperative chemotherapy.
Conclusions
CEA uptrend offers better prediction of survival outcomes than conventional CEA measurements in patients undergoing hepatectomy for CRLM.
Similar content being viewed by others
References
Brennaer H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383(9927):1490–502.
Engstrand J, Nilsson H, Strömberg C, et al. Colorectal cancer liver metastases: A population-based study on incidence, management and survival. BMC Cancer. 2018;18(1):78. https://doi.org/10.1186/s12885-017-3925-x.
House MG, Ito H, Gonen M, et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg. 2010;210(5):744–52.
Sakamoto K, Honda G, Beppu T, et al. Comprehensive data of 3,820 patients newly diagnosed with colorectal liver metastasis between 2005 and 2007: report of a nationwide survey in Japan. J Hepatobiliary Pancreat Sci. 2018;25(2):115–23.
Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24(33):5313–27.
Labianca R, Nordlinger B, Beretta GD, et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(6):64–72.
Duffy MJ, Lamerz R, Haglund C, et al. Tumor makers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer. 2014;134(11):2513–22.
Araujo RL, Gönen M, Allen P, et al. Positive postoperative CEA is a strong predictor of recurrence for patients after resection for colorectal liver metastases. Ann Surg Oncol. 2015;22(9):3087–93. https://doi.org/10.1245/s10434-014-4358-2.
Neofytou K, Giakoustidis A, Neves MC, et al. Increased carcinoembryonic antigen (CEA) following neoadjuvant chemotherapy predicts poor prognosis in patients that undergo hepatectomy for liver-only colorectal metastases. Langenbecks Arch Surg. 2017;402(4):599–605.
John SK, Robinson SM, Rehman S, et al. Prognostic factors and survival after resection of colorectal liver metastasis in the era of preoperative chemotherapy: an 11-year single-centre study. Dig Surg. 2013;30(4–6):293–301.
Sakamoto Y, Miyamoto Y, Beppu T, et al. Post-chemotherapeutic CEA and CA19-9 are prognostic factors in patients with colorectal liver metastases treated with hepatic resection after oxaliplatin-based chemotherapy. Anticancer Res. 2015;35(4):2359–68.
Okazaki S, Baba H, Iwata N, et al. Carcinoembryonic antigen testing after curative liver resection for synchronous liver metastasis of colorectal cancer: a Japanese multicenter analysis. Surg Today. 2017;47(10):1223–9.
Bredt LC, Rachid AF. Predictors of recurrence after a first hepatectomy for colorectal cancer liver metastases: a retrospective analysis. World J Surg Oncol. 2014. https://doi.org/10.1186/1477-7819-12-391.
Nagai Y, Beppu T, Sakamoto Y, et al. Carcinoembryonic antigen half-life is an early predictor of therapeutic effects in induction chemotherapy for liver metastases from colorectal cancer. Anticancer Res. 2014;34(10):5529–35.
Vauthey JN, Zimmitti G, Kopetz SE, et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2013;258(4):619–26.
Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2015;486(7404):532–6.
Gagnière J, Dupré A, Gholami SS, et al. Is hepatectomy justified for BRAF mutant colorectal lover metastases?: A multi-institutional analysis of 1497 patients. Ann Surg. 2020;271(1):147–54.
Liu W, Zhang W, Xu Y, et al. A prognostic scoring system to predict survival outcome of resectable colorectal liver metastases in this modern era. Ann Surg Oncol. 2021;28(12):7709–18. https://doi.org/10.1245/s10434-021-10143-6.
Okuno M, Goumard C, Kopetz S, et al. RAS mutation is associated with unsalvageable recurrence following hepatectomy for colorectal cancer liver metastases. Ann Surg Oncol. 2018;25(8):2457–66. https://doi.org/10.1245/s10434-018-6517-3.
Tsilimigras DI, Ntanasis-Stathopoulos I, Bagante F, et al. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: a systematic review of the current evidence. Surg Oncol. 2018;27(2):280–8.
Gau L, Ribeiro M, Pereira B, et al. Impact of BRAF mutations on clinical outcomes following liver surgery for colorectal liver metastases: an updated meta-analysis. Eur J Surg Oncol. 2021. https://doi.org/10.1016/j.ejso.2021.05.039.
Dijkstra M, Nieuwenhuizen S, Puijk RS, et al. Primary tumor sidedness, RAS and BRAF mutations and MSI status as prognostic factors in patients with colorectal liver metastases treated with surgery and thermal ablation: results from the Amsterdam Colorectal Liver Met Registry (AmCORE). Biomedicines. 2021;9(8): https://doi.org/10.3390/biomedicines9080962
Wanebo HJ, Rao B, Pinsky CM, et al. Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med. 1978;299(9):448–51.
Clinical practice guidelines for the use of tumor makers in breast and colorectal cancer. Adopted on May, 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol. 1996;14(10):2843-77.
Weiser MR. AJCC 8th edition: colorectal cancer. Ann Surg Oncol. 2018;25(6):1454–5. https://doi.org/10.1245/s10434-018-6462-1.
Clavien PA, Barkun J, Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2):187–96.
Hashiguchi Y, Muro K, Saito Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25(1):1–42.
Couinald C. The anatomy of the liver. Ann Ital Chir. 1992;63(6):693–7.
Gehan EA. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika. 1965;52:203–23.
Yoh T, Seo S, Hatano E, et al. A novel biomarker-based preoperative prognostic grading system for predicting survival after surgery for intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2017;24(5):1351–7. https://doi.org/10.1245/s10434-016-5708-z.
Yoh T, Seo S, Ogiso S, et al. Proposal of a New Preoperative Prognostic Model for Solitary Hepatocellular Carcinoma Incorporating 18F-FDG-PET Imaging with the ALBI Grade. Ann Surg Oncol. 2018;25(2):542–9. https://doi.org/10.1245/s10434-017-6262-z.
Yamamoto H, Murata K, Fukunaga M, et al. Micrometastasis volume in lymph nodes determines disease recurrence rate of stage II colorectal cancer: a prospective multicenter trial. Clin Cancer Res. 2016;22(13):3201–8.
Huang SC, Lin JK, Lin TC, et al. Concordance of carcinoembryonic antigen ratio and response evaluation criteria in solid tumors as prognostic surrogate indicators of metastatic colorectal cancer patients treated with chemotherapy. Ann Surg Oncol. 2015;22(7):2262–8. https://doi.org/10.1245/s10434-014-4228-y.
Saito G, Sadahiro S, Okada K, et al. Relation between carcinoembryonic antigen levels in colon cancer tissue and serum carcinoembryonic antigen levels at initial surgery and recurrence. Oncology. 2016;91(2):85–9.
Pilati P, Mocellin S, Bertazza L, et al. Prognostic value of putative circulating cancer stem cells in patients undergoing hepatic resection for colorectal liver metastasis. Ann Surg Oncol. 2012;19(2):402–8. https://doi.org/10.1245/s10434-011-2132-2.
Hatano E, Okuno M, Nakamura K, et al. Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-ras status for unresectable colorectal liver metastasis (BECK study). J Hepatobiliary Pancreat Sci. 2015;22(8):634–45.
Okuno M, Hatano E, Toda R, et al. Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-RAS status for unresectable colorectal liver metastasis (BECK study): long-term results of survival. J Hepatobiliary Pancreat Sci. 2020;27(8):496–509.
Schnitzbauer AA, Lang SA, Goessmann H, et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liber lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size setting. Ann Surg. 2012;255(3):405–14.
Tsilimigras DI, Ntanasis-Stathopoulos I, Bagante F, et al. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastasis: A systematic review of the current evidence. Surg Oncol. 2018;27(2):280–8.
Kawaguchi Y, Kopetz S, Newhook TE, et al. Mutation status of RAS, TP53, and SMAD4 is superior to mutation status of RAS alone for predicting prognosis after resection of colorectal liver metastases. Clin Cancer Res. 2019;25(19):5843–51.
Mizuno T, Cloyd JM, Vicente D, et al. SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases. Eur J Surg Oncol. 2018;44(5):684–92.
Funding
No financial support was received with respect to this manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
The authors who have taken part in this study declare that they do not have anything to disclose regarding funding or conflicts of interest with respect to this manuscript.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Hori, Y., Seo, S., Yoh, T. et al. Impact of Preoperative CEA Uptrend on Survival Outcomes in Patients with Colorectal Liver Metastasis After Hepatectomy. Ann Surg Oncol 29, 6745–6754 (2022). https://doi.org/10.1245/s10434-022-11973-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-022-11973-8